SAMHD1 and acute myeloid leukemia: Application of both 1st and 2nd generation VLPs to primary AML blasts showed that the efficacy to degrade SAMHD1 and increase Ara-C cytotoxicity was low compared to cell lines (Fig. 2) and varied from donor to donor (Fig. 4).